



1  
0  
0  
1  
0  
0  
0  
1

0  
0  
0  
1  
1  
1  
1  
0  
1  
0  
0  
0  
1  
1  
1  
1  
1  
0

1  
0  
0  
1  
0  
0  
0  
1  
1  
1  
1  
0

**ADVANCE PRECISION THERAPIES  
WITH SCREENING-READY  
NOVEL TARGET PACKAGES**

# THE EXCELLENT-DATA APPROACH TO NOVEL TARGET ID

Indivumed Therapeutics is a biotech company focused on precision oncology. We collaborate with pharmaceutical partners, providing novel screening-ready target packages for the development of innovative cancer therapeutics. We envision a world where precision therapy offers a cure for every cancer patient.

## A CLINICAL STANDARD TO ESTABLISH THE BASICS

Through our global clinical network, we have direct access to high-quality biospecimens and data that are crucial to making all relevant details of a cancer disease transparent. Special procedures, in particular keeping cold ischemia times to under ten minutes, ensure pre-analytically controlled specimens with a very high sample integrity. This preserves the expression of otherwise undetectable therapeutic targets. Samples are paired with 300 different clinical data points and up to ten years of follow-up data. They cover a wide variety of biological backgrounds and regional variances from all over the world.

## UNIQUE DATA AND SAMPLES TO WORK WITH

The excellent quality of our samples enables an in-depth multi-omics approach for matched tumor and normal tissue, where we extract proteomics, phospho-proteomics, transcriptomics, genomics, and miRNA data. Following this approach over decades of collaboration, we can now draw on a unique database that reflects the molecular reality of cancer at an unparalleled level. This is the key to both advanced data analytics and end-to-end comparability across the drug development pipeline.

## BOOSTING THE PHARMACEUTICAL INDUSTRY'S R&D PIPELINES

To maximize the value of our data for pharmaceutical development, we have established a holistic target identification process. Each step in this process is designed to increase the probability of successful therapeutic development further down the pipeline and the chances of a novel drug reaching the market.



nRavel®

## TARGET DISCOVERY – UNRAVELLING TRILLIONS OF DATA POINTS

To explore the entirety of our database for hidden patterns, we have established nRavel® – a proprietary platform for multi-variate data analytics that integrates advanced biomathematical and bioinformatics tools. By combining multi-omic expression signatures and prognostic data in selected cohorts, we identify novel and disease-relevant targets – in the correct tissue and for the correct cohort.

## TARGET VALIDATION – WHERE SAMPLE QUALITY PAYS OFF AGAIN

Once we have identified a target using nRavel®, we validate it in proprietary 2D and 3D cellular models based on immortalized cells or primary cells derived from the original patient cohort used in discovery. These models provide a very accurate recapitulation of the patient's physiological processes while representing the characteristic features of the disease.



## TARGET PACKAGE

## TARGET REFINEMENT – PREPARING THE PACKAGE FOR R&D PARTNERSHIPS

Our IP-protected packages consist of screening-ready targets that are set up for reproducibility within our partners' R&D pipelines. The protein type and biochemical characteristics, cellular location and biological function are biochemically characterized. Proof-of-concept drug screening assays are established for cell-free and cell-based compound screening.

1  
0  
0  
0  
1  
1  
1  
1  
1  
0

0  
1  
0  
0  
1  
1  
1  
1  
1  
0

0  
0  
1  
1  
1  
1  
0



1  
0  
0  
1  
0  
0  
0  
1  
1  
1  
1  
0

1  
0  
0  
1  
0  
0  
0  
1  
1  
1  
1  
0

1  
0  
0  
1  
0  
0  
0  
1  
1  
1  
1  
0

## INDIVUMED THERAPEUTICS

Indivumed GmbH  
Falkenried 88, Bldg. D  
20251 Hamburg, Germany

Tel.: +49-40-4133-830  
Fax: +49-40-4133-8314  
Email: [info@indivumed.com](mailto:info@indivumed.com)  
[www.indivumed-therapeutics.com](http://www.indivumed-therapeutics.com)